Latest news with #JimDavis
Yahoo
a day ago
- Business
- Yahoo
Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks
Quest Diagnostics Inc. (NYSE:DGX) delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance. However, the diagnostic test provider flagged potential headwinds from ongoing tariffs and the significant financial impact if the Protecting Access to Medicare Act (PAMA) is not deferred, setting the stage for a watchful eye on legislative and trade developments. For the second quarter of 2025, the company reported sales of $2.76 billion, a 15.2% increase year-over-year, exceeding the consensus of $2.73 billion. Adjusted earnings reached $2.62 per share, up 11.5%, also surpassing the consensus of $2.58. Also Read: Could Personalized Medicine Be Your Portfolio's Next Big Winner? Find Out 'Demand for our innovative clinical solutions and expanded business from enterprise accounts complemented growth from acquisitions. We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full-year 2025 guidance,' said Jim Davis, chairman, CEO, and president. Revenue per requisition decreased by 0.4%, requisition volume increased 16.3% and organic requisition volume improved by 2.1%. Adjusted Operating income increased 17.3% to $466 million, while the margin improved marginally from 16.6% to 16.9%. During the earnings conference call, a Quest Diagnostics executive indicated that the company experienced some negative impact from tariffs in the second quarter and anticipates this will continue through the third and fourth quarters. Furthermore, the executive reportedly stated that if the Protecting Access to Medicare Act (PAMA) is not deferred for another year, the financial impact to Quest Diagnostics would be approximately $100 million. View more earnings on DGX This suggests that Quest Diagnostics is facing a dual challenge: ongoing costs related to current tariffs and a significant potential financial hit if PAMA provisions are not postponed. The company's future financial performance will likely be closely tied to developments on both of these fronts. Outlook: Quest Diagnostics revised 2025 guidance for revenue from $10.70 billion-$10.85 billion to $10.80 billion-$10.92 billion versus the consensus of $10.79 billion. The company expects adjusted earnings of $9.63-$9.83 compared to prior guidance of $9.55-$9.80 and the consensus of $9.70. Reflecting the positive sentiment from the company's strong results and raised outlook, investment firm William Blair provided its assessment, 'Quest continues to showcase itself as a predictable revenue and earnings grower, and we remain confident in the updated 2025 guide and longer-term targets.'
Yahoo
a day ago
- Business
- Yahoo
Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2024 Year-to-date cash provided by operations of $858 million, up 67.1% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.60 and $8.80; and adjusted diluted EPS is expected to be between $9.63 and $9.83 SECAUCUS, N.J., July 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the second quarter ended June 30, 2025. "Through continued execution of our strategy, we delivered a strong second quarter, with revenues growing 15.2% which includes 5.2% from organic revenues, as well as adjusted EPS growth of 11.5%," said Jim Davis, Chairman, CEO and President. "Demand for our innovative clinical solutions and expanded business from enterprise accounts complemented growth from acquisitions. We also realized productivity gains as we continued to deploy automation and digital technologies across our operations. Given our performance in the quarter and continued utilization trends, we are raising our full year 2025 guidance."Three Months Ended June 30,Six Months Ended June 30, 20252024Change20252024Change (dollars in millions, except per share data)Reported: Net revenues $ 2,761$ 2,39715.2 %$ 5,413$ 4,76313.7 %Diagnostic Information Services revenues $ 2,699$ 2,33315.7 %$ 5,288$ 4,63114.2 %Revenue per requisition (0.4) %— %Requisition volume 16.3 %14.3 % Organic requisition volume 2.1 %0.6 %Operating income (a) $ 438$ 35523.3 %$ 784$ 65519.7 %Operating income as a percentage of net revenues (a) 15.9 %14.8 %1.1 %14.5 %13.7 %0.8 %Net income attributable to Quest Diagnostics (a) $ 282$ 22923.1 %$ 502$ 42318.6 %Diluted EPS (a) $ 2.47$ 2.0321.7 %$ 4.41$ 3.7517.6 %Cash provided by operations $ 544$ 36051.5 %$ 858$ 51467.1 %Capital expenditures $ 108$ 9217.3 %$ 225$ 19614.4 % Adjusted (a): Operating income $ 466$ 39817.3 %$ 872$ 74716.8 %Operating income as a percentage of net revenues 16.9 %16.6 %0.3 %16.1 %15.7 %0.4 %Net income attributable to Quest Diagnostics $ 298$ 26612.3 %$ 549$ 49610.7 %Diluted EPS $ 2.62$ 2.3511.5 %$ 4.83$ 4.3910.0 %(a) For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below. Updated Guidance for Full Year 2025 The company updates its full year 2025 guidance as follows:Updated GuidancePrior GuidanceLowHighLowHigh Net revenues $10.80 billion$10.92 billion$10.70 billion$10.85 billion Net revenues increase 9.4 %10.6 %8.4 %9.9 % Reported diluted EPS $8.60$8.80$8.62$8.87 Adjusted diluted EPS $9.63$9.83$9.55$9.80 Cash provided by operations Approximately $1.55 billionApproximately $1.5 billion Capital expenditures Approximately $500 millionApproximately $500 million Note on Non-GAAP Financial Measures As used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP"). The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, gains and losses associated with changes in the carrying value of our strategic investments, impairment charges and other items. Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables below include reconciliations of non-GAAP adjusted measures to GAAP measures. Conference Call Information Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, passcode: 7895081; or via live webcast on our website at We suggest participants dial in approximately 10 minutes before the call. A replay of the call may be accessed online at or, from approximately 10:30 a.m. Eastern Time on July 22, 2025 until midnight Eastern Time on August 5, 2025, by phone at 866-388-5361 for domestic callers or 203-369-0416 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports. About Quest Diagnostics Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our more than 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. Forward Looking Statements The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, uncertain and volatile economic conditions, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government policies, including related to trade, and regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports. This earnings release, including the attached financial tables, is available online in the Newsroom section at ADDITIONAL TABLES FOLLOW Quest Diagnostics Incorporated and Subsidiaries Consolidated Statements of Operations For the Three and Six Months Ended June 30, 2025 and 2024 (in millions, except per share data) (unaudited) Three Months Ended June 30,Six Months Ended June 30,2025202420252024 Net revenues $ 2,761$ 2,397$ 5,413$ 4,763 Operating costs and expenses and other operating income:Cost of services 1,8181,5933,6073,188 Selling, general and administrative 486416962856 Amortization of intangible assets 39297858 Other operating (income) expense, net (20)4(18)6 Total operating costs and expenses, net 2,3232,0424,6294,108 Operating income 438355784655 Other income (expense):Interest expense, net (67)(44)(134)(87) Other income, net 1331012 Total non-operating expense, net (54)(41)(124)(75) Income before income taxes and equity in earnings of equity method investees 384314660580 Income tax expense (97)(74)(156)(140) Equity in earnings of equity method investees, net of taxes 9—278 Net income 296240531448 Less: Net income attributable to noncontrolling interests 14112925 Net income attributable to Quest Diagnostics $ 282$ 229$ 502$ 423 Earnings per share attributable to Quest Diagnostics' common stockholders:Basic $ 2.51$ 2.05$ 4.48$ 3.79 Diluted $ 2.47$ 2.03$ 4.41$ 3.75 Weighted average common shares outstanding:Basic 112111112111 Diluted 113112113112 Quest Diagnostics Incorporated and Subsidiaries Consolidated Balance Sheets June 30, 2025 and December 31, 2024 (in millions, except per share data) (unaudited) June 30,2025December 31,2024 AssetsCurrent assets:Cash and cash equivalents $ 319$ 549 Accounts receivable, net 1,4191,304 Inventories 187188 Prepaid expenses and other current assets 273351 Total current assets 2,1982,392 Property, plant and equipment, net 2,1202,113 Operating lease right-of-use assets 655651 Goodwill 8,8838,856 Intangible assets, net 1,7061,763 Investments in equity method investees 136123 Other assets 271255 Total assets $ 15,969$ 16,153 Liabilities and Stockholders' EquityCurrent liabilities:Accounts payable and accrued expenses $ 1,349$ 1,394 Current portion of long-term debt 504602 Current portion of long-term operating lease liabilities 171173 Total current liabilities 2,0242,169 Long-term debt 5,1695,615 Long-term operating lease liabilities 540535 Other liabilities 890938 Redeemable noncontrolling interest 8183 Stockholders' equity:Quest Diagnostics stockholders' equity:Common stock, par value $0.01 per share; 600 shares authorized as of both June 30, 2025 and December 31, 2024; 162 shares issued as of both June 30, 2025 and December 31, 2024 22 Additional paid-in capital 2,3322,361 Retained earnings 9,6829,360 Accumulated other comprehensive loss (16)(88) Treasury stock, at cost; 50 and 51 shares as of June 30, 2025 and December 31, 2024, respectively (4,772)(4,857) Total Quest Diagnostics stockholders' equity 7,2286,778 Noncontrolling interests 3735 Total stockholders' equity 7,2656,813 Total liabilities and stockholders' equity $ 15,969$ 16,153 Quest Diagnostics Incorporated and Subsidiaries Consolidated Statements of Cash Flows For the Six Months Ended June 30, 2025 and 2024 (in millions) (unaudited) Six Months Ended June 30,20252024 Cash flows from operating activities:Net income $ 531$ 448 Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization 283233 Provision for credit losses 23 Deferred income tax expense (benefit) 8(36) Stock-based compensation expense 4342 Other, net 2616 Changes in operating assets and liabilities:Accounts receivable (115)(113) Accounts payable and accrued expenses (11)(111) Income taxes payable 920 Other assets and liabilities, net 8212 Net cash provided by operating activities 858514 Cash flows from investing activities:Business acquisitions, net of cash acquired (17)(248) Capital expenditures (225)(196) Other investing activities, net 331 Net cash used in investing activities (239)(413) Cash flows from financing activities:Proceeds from borrowings 400— Repayments of debt (1,001)(301) Exercise of stock options 4228 Employee payroll tax withholdings on stock issued under stock-based compensation plans (42)(23) Dividends paid (174)(163) Distributions to noncontrolling interest partners (29)(18) Other financing activities, net (50)(39) Net cash used in financing activities (854)(516) Effect of exchange rate changes on cash and cash equivalents and restricted cash 5— Net change in cash and cash equivalents and restricted cash (230)(415) Cash and cash equivalents and restricted cash, beginning of period 549686 Cash and cash equivalents and restricted cash, end of period $ 319$ 271 Cash paid during the period for:Interest $ 145$ 105 Income taxes $ 110$ 118 Notes to Financial Tables 1) The computation of basic and diluted earnings per common share is as follows: Three Months Ended June 30,Six Months EndedJune 30,2025202420252024(in millions, except per share data) Amounts attributable to Quest Diagnostics' common stockholders:Net income attributable to Quest Diagnostics $ 282$ 229$ 502$ 423 Less: earnings allocated to participating securities 1122 Earnings available to Quest Diagnostics' common stockholders - basic and diluted $ 281$ 228$ 500$ 421 Weighted average common shares outstanding - basic 112111112111 Effect of dilutive securities:Stock options and performance share units 1111 Weighted average common shares outstanding - diluted 113112113112 Earnings per share attributable to Quest Diagnostics' common stockholders:Basic $ 2.51$ 2.05$ 4.48$ 3.79 Diluted $ 2.47$ 2.03$ 4.41$ 3.75 2) The following tables reconcile reported GAAP results to non-GAAP adjusted results: Three Months Ended June 30, 2025(dollars in millions, except per share data)Operating incomeOperating income as a percentage of net revenuesIncome tax expense (e)Equity in earnings of equity method investees, net of taxesNet income attributable to Quest DiagnosticsDiluted EPS As reported $ 43815.9 %$ (97)$ 9$ 282$ 2.47 Restructuring and integration charges (a) 70.3(2)—50.04 Other charges (b) 281.0(6)—220.19 Gains and losses on investments (c) ——1(1)(2)(0.01) Other gains (d) (46)(1.7)12—(34)(0.30) Amortization expense 391.4(11)—280.25 ETB ——(3)—(3)(0.02) As adjusted $ 46616.9 %$ (106)$ 8$ 298$ 2.62Six Months Ended June 30, 2025(dollars in millions, except per share data)Operating incomeOperating income as a percentage of net revenuesIncome tax expense (e)Equity in earnings of equity method investees, net of taxesNet income attributable to Quest DiagnosticsDiluted EPS As reported $ 78414.5 %$ (156)$ 27$ 502$ 4.41 Restructuring and integration charges (a) 260.5(7)—190.17 Other charges (b) 300.6(6)—240.21 Gains and losses on investments (c) ——1(1)(2)(0.01) Other gains (d) (46)(0.9)14(8)(40)(0.36) Amortization expense 781.4(20)—580.51 ETB ——(12)—(12)(0.10) As adjusted $ 87216.1 %$ (186)$ 18$ 549$ 4.83Three Months Ended June 30, 2024(dollars in millions, except per share data)Operating incomeOperating income as a percentage of net revenuesIncome tax expense (e)Equity in earnings of equity method investees, net of taxesNet income attributable to Quest DiagnosticsDiluted EPS As reported $ 35514.8 %$ (74)$ —$ 229$ 2.03 Restructuring and integration charges (a) 100.4(3)—70.06 Other charges (b) 40.2——40.03 Gains and losses on investments (c) ——(3)960.05 Amortization expense 291.2(8)—210.19 ETB ——(1)—(1)(0.01) As adjusted $ 39816.6 %$ (89)$ 9$ 266$ 2.35Six Months Ended June 30, 2024(dollars in millions, except per share data)Operating incomeOperating income as a percentage of net revenuesIncome tax expense (e)Equity in earnings of equity method investees, net of taxesNet income attributable to Quest DiagnosticsDiluted EPS As reported $ 65513.7 %$ (140)$ 8$ 423$ 3.75 Restructuring and integration charges (a) 270.6(7)—200.17 Other charges (b) 70.2——70.06 Gains and losses on investments (c) ——(3)960.05 Amortization expense 581.2(15)—430.39 ETB ——(3)—(3)(0.03) As adjusted $ 74715.7 %$ (168)$ 17$ 496$ 4.39 (a) For each of the three and six months ended June 30, 2025 and 2024, the pre-tax impact represents costs primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations:Three Months Ended June 30,Six Months Ended June 30,2025202420252024(dollars in millions) Cost of services $ 1$ 1$ 7$ 14 Selling, general and administrative 691913 Operating income $ 7$ 10$ 26$ 27 (b) For both the three and six months ended June 30, 2025, the pre-tax impact primarily represents a $24 million impairment charge on certain long-lived assets related to the potential exit of a business. Additionally, each of the three and six months ended June 30, 2025 and June 30, 2024 include losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions. The following table summarizes the pre-tax impact of these other charges on our consolidated statements of operations:Three Months Ended June 30,Six Months Ended June 30,2025202420252024(dollars in millions) Selling, general and administrative $ —$ 1$ —$ 1 Other operating (income) expense, net 283306 Operating income $ 28$ 4$ 30$ 7 (c) For each of the three and six months ended June 30, 2025 and 2024, the pre-tax impact represents gains and losses associated with changes in the carrying value of our strategic investments, recorded in equity in earnings of equity method investees, net of taxes, and other income, net. (d) The three and six months ended June 30, 2025 include a $46 million pre-tax gain, recorded in other operating (income) expense, net, from a payroll tax credit under the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") associated with the retention of employees. Additionally, the six months ended June 30, 2025 includes an $8 million gain, recorded in equity in earnings of equity method investees, net of taxes, representing a non-recurring gain related to a lease. (e) For restructuring and integration charges, other gains/charges, gains and losses on investments and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of 25.5% for both 2025 and 2024. 3) The outlook for adjusted diluted EPS represents management's estimates for the full year 2025 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2025. Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, which are difficult to predict. The following table reconciles our 2025 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS: LowHigh Diluted EPS $ 8.60$ 8.80 Restructuring and integration charges (a) 0.240.24 Amortization expense (b) 1.031.03 Other charges (c) 0.270.27 Other gains (d) (0.36)(0.36) Gains and losses on investments (0.01)(0.01) ETB (0.14)(0.14) Adjusted diluted EPS $ 9.63$ 9.83 (a) Represents estimated pre-tax charges of $37 million primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%. (b) Represents estimated pre-tax amortization expenses of $157 million. Income tax benefits were primarily calculated using a combined statutory income tax rate of 25.5%. (c) Principally represents a $24 million pre-tax impairment charge on certain long-lived assets related to the potential exit of a business. Also includes estimated pre-tax net charges of $12 million associated with the increase in the fair value of the contingent consideration accrual associated with previous acquisitions. Income tax benefits on the impairment charge were calculated using a combined statutory income tax rate of 25.5%. No income tax benefits were recorded on the changes associated with the contingent consideration accrual. (d) Includes a pre-tax gain of $46 million related to a payroll tax credit under the CARES Act associated with the retention of employees. Also, includes a non-recurring pre-tax gain of $8 million related to a lease. Income tax impacts on the gains were calculated using a combined statutory income tax rate of 25.5%. View original content to download multimedia: SOURCE Quest Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Boston Globe
10-07-2025
- General
- Boston Globe
More than just the North End: The very best Italian restaurants around Boston
.bofbpic img { width: 100%; height: auto; } Carlo's Cucina Italiana Carlo's Cucina Italiana Jim Davis/Globe staff/File Why hassle with the North End when there's Carlo's Cucina Italiana in Allston? This beloved and reasonably priced restaurant has you covered, with all the arancini, frutti di mare, and chicken parm your heart desires. Inhale lusty house specialties such as vitello Carlo (veal stuffed with artichoke hearts, fontina cheese, and prosciutto in tomato sauce) and ravioli Antonio (lobster ravioli with salmon in lemon vodka sauce) beside seaside murals, underneath a ceiling painted to look like the sky. Address: 131 Brighton Avenue, Allston Phone: 617-254-9759 Find online: .bofbpic img { width: 100%; height: auto; } Coppa Coppa Brooke Elmore A meat-lover's Italian paradiso, wedged into a quietish corner of the South End: Ken Oringer oversees a lavish, mainly-meaty menu offering salumi (the beef-heart pastrami is essential), pizza, and redolent, rich pork tagliatelle. The ideal second-date destination, complete with a mellow trattoria vibe. Address: 253 Shawmut Avenue, South End Phone: Find online: .bofbpic img { width: 100%; height: auto; } Delfino Delfino In Roslindale Square, look for the purple storefront with the gold stars: This is Delfino, a perfect neighborhood restaurant, always packed with regulars who know the longtime staffers by name. They swear by linguine loaded with seafood, Bolognese, and open-faced lobster ravioli, along with charmingly old-school dishes such as the Figgy Piggy, pork tenderloin with fig demi-glace, prosciutto, and garlic mashed potatoes. Bring the family, take a date, celebrate a birthday. It works for every occasion. Address: 754 South Street, Roslindale Phone: 617-327 8359 Find online: .bofbpic img { width: 100%; height: auto; } Giulia Giulia Erik Jacobs Consistency, excellence, and the pasta table: These are just a few of the reasons to love chef Michael Pagliarini's soulful, seasonal Italian restaurant near Porter Square. It's hard to come here and not get the pappardelle with braised wild boar, but everything on the menu is worth ordering … and then there are the specials. Whatever else happens, do not fail to order one of the wonderful desserts. And if you have a larger group, reserve the pasta table. By day, it's a surface upon which to make tagliatelle and agnolotti; by night, it's a place to eat it, as part of Pagliarini's carefully constructed tasting menus. Address: 1682 Massachusetts Avenue, Cambridge Phone: 617-441-2800 Find online: .bofbpic img { width: 100%; height: auto; } La Padrona La Padrona Brian Samuels A triumphant splurge in the new Raffles Boston hotel, La Padrona comes courtesy of Rialto legend Jody Adams. Ascend a striking staircase to a room that conjures a Fellini-era steakhouse, with secluded banquettes and muted lighting — lending everyone an air of mystery. Not muted is the food: tart charred cabbage drizzled with anchovy butter; pristine tuna crudo ringed in crispy chili peppers; and creamy, cheesy strands of tagliatelle with a zag of balsamic, properly poured tableside. This is Boston's newest big night out. Address: 38 Trinity Place, Back Bay Phone: 617-898-0010 Find online: .bofbpic img { width: 100%; height: auto; } MIDA MIDA Erin Clark/Globe staff/File Get yourself a chef who worked at Radius and Corton, find a sweet little room with a wraparound bar and an open kitchen, and craft a menu filled with handmade pasta: You've got a neighborhood winner. It's no wonder Douglass Williams' MIDA has expanded from its original South End location to Newton, Fenway, and East Boston. Even simple things like the mixed greens salad are done well. Don't miss Mangia Mondays, when $80 gets you five dishes of pasta (gluten-free options available), salad, and bread for two. Address: 782 Tremont Street, South End, and other locations Phone: Find online: .bofbpic img { width: 100%; height: auto; } Pammy's Pammy's Natasha Moustache On the drinks menu: homemade limoncello and $5 Miller High Life. Such is Pammy's. Always classy, never pretentious. The staff cook and serve up the best Bolognese you've ever had, as well as cuts of meat and fish typically reserved for Michelin-starred spots, while also wearing jeans and cracking jokes like old friends. Come in and sit at the bar and order à la carte. Or make an evening of it with the prix-fixe, 'choose your own adventure' menu and sit with the fancy reservation folk in the back. Address: 928 Massachusetts Avenue, Cambridge Phone: Find online: Related : .bofbpic img { width: 100%; height: auto; } SRV SRV Dina Rudick/Globe staff/File This stylish wine bar pays tribute to the Serene Republic of Venice with pre-meal aperitivi and cicchetti (small plates), pasta made with hand-milled flour, and other Italian delights. With a spritz in hand, enjoy artichoke arancini, tonnarelli pasta tangled with asparagus and truffles, duck with chickpea pancakes, and gelati and sorbetto in an array of enticing flavors. The food, from chef Michael Lombardi (Del Posto, Si Cara) and team, is elegant but relaxed; the atmosphere at this restaurant from the Coda Group (Baleia, Gufo, The Salty Pig) is welcoming. Bonus: the beautiful back patio. Address: 569 Columbus Avenue, South End Phone: Find online: .bofbpic img { width: 100%; height: auto; } Tonino Tonino Gabby Riggieri The Italian restaurant Jamaica Plain had been waiting for, Tonino is tiny, busy, and delicious. Reserve in advance to eat all the carbs from chef Luke Fetbroth (Giulia, Sarma): pasta dishes such as Taleggio cappelletti, bucatini with anchovy-chile butter, and cavatelli with sausage and broccoli rabe, but especially the excellent, focaccia-adjacent pan pizza. Add a salad to lighten things up, sip Lambrusco, and put a cap on the evening with some ricotta cheesecake. Address: 669A Centre Street, Jamaica Plain Phone: 617-524-9217 Find online: Boston Globe Best of the Best were selected by Globe newsroom staff and correspondents, and limited to Boston, Cambridge, Somerville, and Brookline. We want to hear from you: ? Advertisement @font-face { font-family: BentonSansCond-Regular; src: url(" format('woff2'), url(" format('woff'); } @font-face { font-family: BentonSansCond-Bold; src: url(" format('woff2'), url(" format('woff'); } @font-face { font-family: 'Miller'; src: url(' format('woff2'), url(' format('woff'); } @font-face { font-family: "Miller Headline Bold"; src: url(" format("eot"), url(" format("woff"), url(" format("truetype"), url(" format("svg"); } @font-face { font-family: "Miller"; src: url(" format("woff2"), url(" format("woff"); } @font-face { font-family: Miller-Banner; src: url(" format("woff2"), url(" format("woff"); font-style: normal; font-weight: 400; } .bofb__container { display: block; max-width: 690px; margin-left: auto; margin-right: auto; } .bofb_hed { font-family: "Miller-Banner", "Times New Roman", Times, Georgia, serif; line-height: 1.2; font-size: 28px; font-weight: 200; text-align: center; letter-spacing: .5px; color: #000; display: block; margin: 16px 15px 16px 0px; text-decoration: none; } .darklinetop { width: 100%; display: block; border-bottom: 0px solid rgba(86, 132, 155,1); height: 2px; background: #005DC7; margin: 10px 0px; text-align: center; margin-left: auto; margin-right: auto; } .bofboverline { font-family: "BentonSansCond-Regular", "Impact", "Arial Narrow", "Helvetica", sans-serif; text-align: left; line-height: 1.5; font-size: .75rem; letter-spacing: .45px; color: #9e1511; padding: 8px 0px 0px 0px; text-transform: uppercase; } { font-family: "Miller-Banner", "Times New Roman", Times, Georgia, serif; text-align: left; line-height: 1.25; font-size: 1.75rem; letter-spacing: .25px; color: #000; padding: 8px 0px 10px 0px; } .bfbblurbcopy { font-family: "Georgia", "Times New Roman", Times, sans-serif, serif; text-align: left; line-height: 1.8; font-size: 18px; letter-spacing: .25px; color: #000; padding: 8px 0px 0px 0px; } .bfbphotocredit_caption { font-family: "BentonSansCond-Regular", "Impact", "Arial Narrow", "Helvetica", sans-serif; text-align: right; line-height: 1.5; font-size: 12px; letter-spacing: .25px; color: #000; padding: 8px 0px 0px 0px; } .bfbphotocredit_caption span { font-family: "BentonSansCond-Regular", "Impact", "Arial Narrow", "Helvetica", sans-serif; color: #666; text-transform: uppercase; } .dipupnext__content { width: 100%; display: grid; grid-template-columns: 3fr; grid-column-gap: 40px; /* Adjust the gap between columns */ margin-top: 10px; } .dipupnext:not(:last-child) { border-right: 1px solid #fff; /* Add your desired border color and style */ padding-right: 20px; /* Adjust padding if necessary */ margin-right: -1px; /* Compensate for the added border width */ } @media screen and (min-width: 500px) { .dipupnext__content { grid-template-columns: 1fr 1fr 1fr; grid-column-gap: 40px; } .dipupnext:not(:last-child) { border-right: 1px solid #005DC7; /* Add your desired border color and style */ padding-right: 20px; /* Adjust padding if necessary */ margin-right: -1px; /* Compensate for the added border width */ } } .bofbaddress { font-family: "MillerHeadline-Bold", "Times New Roman", Times, Georgia, serif; font-weight: 600; text-align: left; font-size: 16px; line-height: 1; margin-top: .5rem; letter-spacing: 0px; color: #000; width: 100%; } .bofbaddressblurb { font-family: "Georgia", "Times New Roman", Times, sans-serif, serif; text-align: left; line-height: 1.5; font-size: .95rem; letter-spacing: .25px; color: #000; padding: 2px 0px 0px 0px; } @media (min-width: 650px) { .bofb_hed { font-family: "Miller-Banner", "Times New Roman", Times, Georgia, serif; line-height: .8; font-size: 28px; font-weight: 200; text-align: center; letter-spacing: .5px; color: #000; display: block; margin: 16px 15px 6px 0px; } } .theme-dark .bofb_hed { color: #fff; } .newsletter{ display: block; margin-left: auto; margin-right: auto; max-width: 700px; } .theme-dark .bofbblurbhed { color: #fff; } .theme-dark .bfbphotocredit_caption { color: #fff; } .theme-dark .bofboverline { color: #fff; } .theme-dark .bfbblurbcopy { color: #fff; } .theme-dark .bofbaddress { color: #fff; } .theme-dark .bofbaddressblurb { color: #fff; }
Yahoo
17-06-2025
- Business
- Yahoo
The 5 Most Interesting Analyst Questions From Quest's Q1 Earnings Call
Quest Diagnostics delivered a strong start to the year, with revenue and adjusted profit both coming in above Wall Street expectations. Management attributed the robust performance to higher sales volumes, contributions from recent acquisitions, and expanded partnerships with large enterprise accounts. CEO Jim Davis pointed to particularly strong demand in advanced diagnostics, new health plan contracts, and the successful integration of acquired businesses as key factors supporting growth. Davis also highlighted the company's ongoing efforts to improve productivity through increased automation and the deployment of artificial intelligence in laboratory operations. Is now the time to buy DGX? Find out in our full research report (it's free). Revenue: $2.65 billion vs analyst estimates of $2.62 billion (12.1% year-on-year growth, 1.3% beat) Adjusted EPS: $2.21 vs analyst estimates of $2.15 (2.9% beat) Adjusted EPS guidance for the full year is $9.68 at the midpoint, roughly in line with what analysts were expecting Operating Margin: 13%, in line with the same quarter last year Sales Volumes rose 12.4% year on year (1.5% in the same quarter last year) Market Capitalization: $20.33 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Luke Sergott (Barclays) asked about the sustainability of organic volume growth and if recent trends would persist. CEO Jim Davis explained that, after adjusting for weather and leap year effects, volume trends are consistent with the company's expectations and are tracking with late-2024 levels. Kevin Caliendo (UBS) inquired about Quest's tariff exposure and supply chain resilience. Davis stated that less than 1% of supply costs are directly sourced from China and that most critical reagents are U.S.-manufactured, minimizing tariff risks. Patrick Donnelly (Citi) questioned margin pacing for the rest of the year and the performance of LifeLabs. CFO Sam Samad confirmed that margin seasonality is expected to follow historical trends and that LifeLabs is showing steady progress toward corporate margin targets. Noah Kava (Jefferies) sought clarity on the early commercial traction and reimbursement pathway for the Haystack MRD cancer recurrence test. Davis said commercial orders have begun, with reimbursement submissions underway and additional clinical evidence expected in coming quarters. David Westenberg (Piper Sandler) asked about the financial benefits and performance indicators for Quest's collaboration with Google Cloud and use of generative AI. Samad outlined that these efforts will improve data analytics efficiency, support faster customer service, and enable AI-based tools for physicians and patients, with success measured by speed and accuracy of information delivery. In the quarters ahead, the StockStory team will be monitoring (1) the adoption rates of new advanced diagnostic tests such as the AD-Detect Alzheimer's panel and Haystack MRD, (2) progress on integration and margin improvement at recently acquired businesses like LifeLabs, and (3) efficiency gains from automation and Project Nova modernization. The evolution of enterprise partnerships and regulatory updates will also be important signposts for Quest's trajectory. Quest currently trades at $182, up from $161.98 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Auto Blog
07-06-2025
- Automotive
- Auto Blog
Walmart is selling a $130 jump starter box for just $38, and shoppers say it's ‘outstanding and powerful'
SALEM, NH - NOVEMBER 28: A car with Massachusetts plates pulls into the Walmart parking lot at the store on Route 28 in Salem, N.H. on Thanksgiving morning. (Photo by Jim Davis/The Boston Globe via Getty Images) Autoblog aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. You can never be too careful. That age-old cliché rings especially true for drivers. Whether you're commuting every day to work or embarking on weekend road trips across state lines, storing a jump starter in your roadside emergency kit can be the difference between getting stranded and bringing a dead battery back to life, at least for a little while. Numerous Walmart shoppers have called the Gooloo Jump Starter Box a 'life saver,' and it's currently on sale for $38 — a massive savings of 71%. Gooloo Jump Starter Box, $38 (was $130) at Walmart When the 12-volt battery dies in most vehicles, the starter lacks a power source to crank the engine and run the alternator, which keeps your electrical systems alive. This Gooloo-branded gadget is itself a battery with a pair of clamps included in the box. When connected to the terminals on your depleted car battery, the jumper box provides temporary power for the starter to at least get your motor running. Unlike the analog jumper cable sets of yesteryear, the jumper box is rechargeable. Using nothing more than a USB-C cable, you can jump-start your car as many as 30 times or keep it juiced in your cargo tray for up to a year before charging it again. You'll also have access to two onboard USB Type-A outputs, one of which can quick-charge, for powering up your phone or other devices during your travels. A 400-lumen light with three flash modes makes it possible to see in the dark or signal to others that you're in distress. 'My van wouldn't start, and when AAA came out, they had something similar. This little thing started my van TWICE before I had to charge it,' said one shopper. 'Now I have a new battery but I'm so happy to have it as a backup just in case. Would 10/10 recommend, especially for women like me that go on long trips alone.' Another customer wrote, 'Outstanding and powerful auto/truck jump starter!' said one shopper. 'Don't wait until you are stuck with a dead battery. Go buy this now and rest easy!' With over 1,900 five-star ratings, plenty of satisfied customers agree that the Gooloo Jump Starter Box was well worth the price even before it went on sale. At $38, it's a no-brainer.
